Overview

Thymoglobulin in Cadaver Donor

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

To determine the efficacy and Security of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers in graft biopsies Security:To demonstrate that the administration of Thymoglobulin does not have side effects in renal recipients.

Phase:

Phase 2

Details

Lead Sponsor:

Instituto de Investigación Hospital Universitario La Paz

Collaborator:

Hospital de Santa Maria, Portugal

Treatments:

Thymoglobulin